Panel Discussion: The Bengaluru Bet: How GCCs are redefining India Pharma Inc

Panellists in this video: • Dr Mahesh Bhalgat, CEO and Founder, AAPM Therapeutics (MODERATOR) • Dr Gursharan Singh, GM – Medical Sciences, Clinical Development, Biocon • Dr Raghavender Gunda, Head-R&D QA, VJ Biosciences • Mr Shrenik Kole, VP and Head Sterile Product Development, Micro Lab • Dr Goutam Pujari, VP, Clinical Research and R&D, Apotex Research • Dr Manoj Kumar Singh, Sr VP, Micro Labs • Mr Siddalingaswamy, VP Operations, Zuventus Healthcare Limited (Emcure Group) • Mr Kesavalu Purushothaman, GM – Formulation Development, Lyrus Life Sciences • Dr Nandakumar Sundaramoorthy, Associate VP, OneSource Specialty Pharma Key Highlights: [1] Pharma GCCs in India need to move beyond execution and take ownership of portfolio strategy, clinical development and medical affairs [2] India’s proven capabilities in global clinical trials, regulatory approvals and biosimilars create a strong case for shifting higher-value pharma work from the US and Europe to Indian GCCs [3] GCCs can potentially deliver 50–60% savings in FTE costs while improving efficiency by leveraging India’s talent pool and emerging AI capabilities [4] Complex R&D activities such as novel formulations, complex injectables and sameness/similarity studies should increasingly be brought into Indian GCCs to move them up the value chain [5] AI, automation and digitisation are emerging as key enablers across clinical, quality, manufacturing and analytical functions, including automated review, investigations and faster batch release [6] India’s GCC talent is increasingly taking on global leadership responsibilities, with areas such as clinical development, regulatory strategy and pharmacovigilance being significantly driven from India [7] The next phase of GCC growth will depend on combining talent with advanced technology, including generative AI, data analytics, computational tools and AI applications in pharma operations [8] Stronger collaboration between GCCs, pharma companies, startups, academia and institutions such as IITs and IISc can accelerate innovation and help build India into a global pharma centre of excellence. The post Panel Discussion: The Bengaluru Bet: How GCCs are redefining India Pharma Inc appeared first on Express Pharma.